Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th International Congress of Immunology
(Thomson Reuters ONE) -
Novartis International AG /
Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th
International Congress of Immunology
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* The Basic Immunology Prize is awarded to Drs. Tim R. Mossman and Robert L.
Coffman for their work in defining subsets of T helper cells that advanced
the understanding of infectious, autoimmune and allergic diseases.
* The Clinical Immunology Prize is awarded to Dr. James Allison for his work
in understanding how cancers evade the immune system and developing
therapies to help enhance the body's immune response to cancers.
Basel, June 17, 2013 - The Novartis Prizes for Immunology are awarded to three
scientists for their groundbreaking research into the biology of immune system T
cells that advanced the prevention and treatment of a variety of diseases. The
Prize ceremony will take place at the 15(th) International Congress of
Immunology in Milan, Italy on August 23, 2013.
The Novartis Prize for Basic Immunology 2013 is shared by Tim R. Mossman, Ph.D.,
Director of the Human Immunology Center at the University of Rochester and
Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer at
Dynavax.
While working together in the 1980s at DNAX Research Institute in Palo Alto, CA,
they determined the distinct functions of two T-helper cell subsets - with Th1
playing a major role in cellular immunity critical for resistance to infections,
whereas Th2 cells can induce allergic diseases. They also found that
dysregulation of Th1 and Th2 cell functions was implicated in many immunological
diseases.
"The fundamental discovery by Drs. Mossman and Coffman of the specific types of
T cells that helped either cellular or humoral (antibody-mediated) immunity
revolutionized our understanding of how the immune system works, and led to
major advances in designing therapies for infectious, inflammatory and allergic
diseases and in vaccine design," said Dhaval Patel, Head, NIBR Europe and Global
Head of Autoimmunity, Transplantation and Immunology.
The Novartis Prize for Clinical Immunology 2013 is awarded to James Allison,
Ph.D., Chair of The University of Texas MD Anderson Cancer Center, Department of
Immunology, for research that is thwarting cancer's ability to evade attack by
the immune system.
In the 1990s his study in mice demonstrated that CTLA-4, a molecule expressed on
T cells, blocks the body's natural immune response. An antibody he developed
against CTLA-4 inhibits tumor growth in mice, and has evolved into Ipilimumab, a
successful treatment for advanced-stage melanoma in humans.
"I admire Dr. Allison's vision, drive, and perseverance in testing his
immunomodulatory approach in humans, which will positively impact many patients
with cancer," said Patel. "His discovery has not only given us new tools, but a
new way of thinking about fighting cancer."
About the Novartis Prizes for Immunology
Established in 1990, The Novartis Prizes for Immunology are awarded every three
years for breakthrough contributions to the fields of basic and clinical
immunology as judged by an independent panel of experts. Each of the two Prizes
is endowed for 100,000 CHF. One fifth of each prize is awarded in personal
recognition of exceptional individual achievements, while the remainder is
intended to support the prize winner's research. The prizes were established
both to honor outstanding research in the most challenging areas of immunology-
based science and to increase interactions between scientists in academia and
industry.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 129,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line :
+41 61 324 2200
Eric Althoff Mariellen Gallagher
Novartis Global Media Relations Novartis Institutes for BioMedical
+41 61 324 7999 (direct) Research
+41 79 593 4202 (mobile) +1 617 871 7665 (direct)
eric.althoff(at)novartis.com +1 617 909 9137 (mobile)
mariellen.gallagher(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1709714/566696.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1709714]
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2013 - 07:15 Uhr
Sprache: Deutsch
News-ID 270069
Anzahl Zeichen: 7322
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Three Scientists to Receive Prestigious Novartis Prizes for Immunology at 15th International Congress of Immunology"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
